LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Aandelen Lijst・Gilead Sciences Inc.

Gilead Sciences Inc.

Open

SectorGezondheidszorg

129.55 0.05

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

129.32

Max

130.63

Belangrijke statistieken
By Trading Economics
Inkomsten	-162M 2B
Verkoop	-965M 7B
K/W Sectorgemiddelde	17.837 49.888
EPS	2.03
Dividendrendement	2.37
Winstmarge	29.037
Werknemers	17,000
EBITDA	1.2B 3.5B

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+23.96% upside

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	2.37% 2.38%
Volgende Winsten	6 aug 2026
Volgende dividenddatum	29 jun 2026
Volgende Ex Dividend datum	15 jun 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-1.9B 163B
Vorige openingsprijs	129.5
Vorige sluitingsprijs	129.55

Nieuwssentiment

By Acuity

18%

82%

22 / 344 Rangschikking in Healthcare

Gilead Sciences Inc. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 mei 2026, 20:49 UTC

Winsten

Gilead Sciences Expects Loss This Year on Acquired R&D Expenses

7 apr 2026, 14:24 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion -- Update

7 apr 2026, 12:53 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion

4 jun 2026, 20:15 UTC

Acquisities, Fusies, Overnames

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

8 mei 2026, 08:10 UTC

Winsten

Gilead Stock Falls After Earnings. A Big Acquisition Spree Is Coming at a Cost. -- Barrons.com

8 mei 2026, 08:08 UTC

Winsten

Acquisities, Fusies, Overnames

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 mei 2026, 22:33 UTC

Winsten

Acquisities, Fusies, Overnames

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 mei 2026, 21:09 UTC

Winsten

Gilead Earnings Show HIV Drugs Continue to Shine. Why the Guidance Cut? -- Barrons.com

7 mei 2026, 20:51 UTC

Winsten

Gilead Earnings Show HIV Drugs Continue to Shine. Why the Guidance Cut? -- Barrons.com

7 mei 2026, 20:06 UTC

Winsten

Gilead Sciences Raises 2026 View To Sales $30B-$30.4B >GILD

7 mei 2026, 20:05 UTC

Winsten

Gilead Sciences Sees 2026 Adj Loss/Shr 65c-Adj Loss/Shr $1.05 >GILD

7 mei 2026, 20:05 UTC

Winsten

Gilead Sciences Sees 2026 Loss/Shr $2.85-Loss $3.25 >GILD

7 mei 2026, 20:02 UTC

Winsten

Gilead Sciences: Biktarvy Sales Increased 7% Yr-Over-Yr to $3.4B >GILD

7 mei 2026, 20:01 UTC

Winsten

Gilead Sciences 1Q Rev $6.96B >GILD

7 mei 2026, 20:01 UTC

Winsten

Gilead Sciences 1Q Adj EPS $2.03 >GILD

7 mei 2026, 20:01 UTC

Winsten

Gilead Sciences 1Q Total Liver Disease Sales $767M >GILD

7 mei 2026, 20:01 UTC

Winsten

Gilead Sciences 1Q EPS $1.61 >GILD

28 apr 2026, 12:45 UTC

Acquisities, Fusies, Overnames

Gilead Sciences Completes Acquisition Of Arcellx Ahead Of Potential Commercial Launch Of Anito-cel >GILD

17 apr 2026, 12:32 UTC

Acquisities, Fusies, Overnames

Gilead Sciences Extends Arcellx Tender Offer >GILD ACLX

17 apr 2026, 12:30 UTC

Acquisities, Fusies, Overnames

Gilead Receives All Required Regulatory Approvals For The Acquisition Of Arcellx And Extends Tender Offer >GILD

7 apr 2026, 14:36 UTC

Acquisities, Fusies, Overnames

EQT Life Sciences: The Deal Is Expected to Close in 2Q of 2026

7 apr 2026, 14:35 UTC

Acquisities, Fusies, Overnames

EQT Life Sciences: Gilead Plans to Finance Transaction With Cash and Senior Unsecured Notes

7 apr 2026, 14:34 UTC

Acquisities, Fusies, Overnames

EQT Life Sciences: Gilead Will Also Buy TUB-030

7 apr 2026, 14:28 UTC

Acquisities, Fusies, Overnames

EQT Life Sciences to Exit Minority Stake in Tubulis via Sale to Gilead Sciences for Up to $5B

7 apr 2026, 14:23 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Gilead Buying Another Cancer-Drug Partner -- Market Talk

7 apr 2026, 13:55 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Gilead Continues Buying Spree with Tubulis Deal -- Market Talk

7 apr 2026, 13:14 UTC

Acquisities, Fusies, Overnames

Gilead Adds to Cancer Pipeline With Acquisition Worth Up to $5 Billion -- Barrons.com

7 apr 2026, 12:30 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Finance Tubulis Deal With Cash on Hand, Senior Unsecured Notes >GILD

7 apr 2026, 12:30 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Tubulis Deal Antibody-Drug Conjugates on Oncology Pipeline >GILD

7 apr 2026, 12:30 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Tubulis Deal Includes Up to $1.85 Billion Contingent Milestone Payments >GILD

Peer Vergelijking

Prijswijziging

Gilead Sciences Inc. Prognose

Koersdoel

By TipRanks

23.96% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 160.11 USD 23.96%

Hoogste 180 USD

Laagste 122 USD

Gebaseerd op 21 Wall Street-analisten die 12-maands prijsdoelen bieden voor Gilead Sciences Inc. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

21 ratings

Buy

Hold

Sell

Gebaseerd op 21 analisten die aandelenratings hebben gegeven aan Gilead Sciences Inc. - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

22 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.